nodes	percent_of_prediction	percent_of_DWPC	metapath
Boceprevir—Thyroid neoplasm—Riluzole—amyotrophic lateral sclerosis	0.0416	0.0713	CcSEcCtD
Boceprevir—CTSK—forelimb—amyotrophic lateral sclerosis	0.0352	0.144	CbGeAlD
Boceprevir—CTSK—hindlimb—amyotrophic lateral sclerosis	0.0317	0.13	CbGeAlD
Boceprevir—CTSK—appendage—amyotrophic lateral sclerosis	0.0272	0.111	CbGeAlD
Boceprevir—Cardiac murmur—Riluzole—amyotrophic lateral sclerosis	0.0155	0.0265	CcSEcCtD
Boceprevir—CTSL—embryo—amyotrophic lateral sclerosis	0.012	0.0491	CbGeAlD
Boceprevir—Fungal skin infection—Riluzole—amyotrophic lateral sclerosis	0.0115	0.0197	CcSEcCtD
Boceprevir—Cheilitis—Riluzole—amyotrophic lateral sclerosis	0.0113	0.0193	CcSEcCtD
Boceprevir—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.0111	0.019	CcSEcCtD
Boceprevir—Proctalgia—Riluzole—amyotrophic lateral sclerosis	0.0102	0.0175	CcSEcCtD
Boceprevir—Endophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0173	CcSEcCtD
Boceprevir—Cerebral ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00991	0.017	CcSEcCtD
Boceprevir—Tongue discolouration—Riluzole—amyotrophic lateral sclerosis	0.00991	0.017	CcSEcCtD
Boceprevir—CTSV—medulla oblongata—amyotrophic lateral sclerosis	0.00937	0.0384	CbGeAlD
Boceprevir—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00936	0.0161	CcSEcCtD
Boceprevir—Anorectal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00876	0.015	CcSEcCtD
Boceprevir—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00844	0.0145	CcSEcCtD
Boceprevir—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00844	0.0145	CcSEcCtD
Boceprevir—CTSV—spinal cord—amyotrophic lateral sclerosis	0.00836	0.0342	CbGeAlD
Boceprevir—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00834	0.0143	CcSEcCtD
Boceprevir—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.00815	0.014	CcSEcCtD
Boceprevir—CTSV—MHC class II antigen presentation—KIFAP3—amyotrophic lateral sclerosis	0.00799	0.0463	CbGpPWpGaD
Boceprevir—CTSL—MHC class II antigen presentation—KIFAP3—amyotrophic lateral sclerosis	0.00799	0.0463	CbGpPWpGaD
Boceprevir—CTSS—embryo—amyotrophic lateral sclerosis	0.00791	0.0324	CbGeAlD
Boceprevir—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00788	0.0135	CcSEcCtD
Boceprevir—CTSL—medulla oblongata—amyotrophic lateral sclerosis	0.00765	0.0313	CbGeAlD
Boceprevir—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00762	0.0131	CcSEcCtD
Boceprevir—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.00739	0.0127	CcSEcCtD
Boceprevir—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00717	0.0123	CcSEcCtD
Boceprevir—CTSV—nervous system—amyotrophic lateral sclerosis	0.00704	0.0288	CbGeAlD
Boceprevir—Paranoia—Riluzole—amyotrophic lateral sclerosis	0.00703	0.0121	CcSEcCtD
Boceprevir—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.0069	0.0118	CcSEcCtD
Boceprevir—CTSL—spinal cord—amyotrophic lateral sclerosis	0.00683	0.028	CbGeAlD
Boceprevir—CTSV—central nervous system—amyotrophic lateral sclerosis	0.00678	0.0278	CbGeAlD
Boceprevir—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00671	0.0115	CcSEcCtD
Boceprevir—Apathy—Riluzole—amyotrophic lateral sclerosis	0.00671	0.0115	CcSEcCtD
Boceprevir—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.00665	0.0114	CcSEcCtD
Boceprevir—CTSK—MHC class II antigen presentation—KIFAP3—amyotrophic lateral sclerosis	0.00662	0.0383	CbGpPWpGaD
Boceprevir—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00615	0.0106	CcSEcCtD
Boceprevir—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00578	0.00991	CcSEcCtD
Boceprevir—CTSK—medulla oblongata—amyotrophic lateral sclerosis	0.00577	0.0236	CbGeAlD
Boceprevir—CTSL—nervous system—amyotrophic lateral sclerosis	0.00575	0.0236	CbGeAlD
Boceprevir—CTSL—central nervous system—amyotrophic lateral sclerosis	0.00554	0.0227	CbGeAlD
Boceprevir—CTSS—MHC class II antigen presentation—KIFAP3—amyotrophic lateral sclerosis	0.00545	0.0316	CbGpPWpGaD
Boceprevir—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00545	0.00935	CcSEcCtD
Boceprevir—CTSL—cerebellum—amyotrophic lateral sclerosis	0.00541	0.0222	CbGeAlD
Boceprevir—CTSV—brain—amyotrophic lateral sclerosis	0.00538	0.022	CbGeAlD
Boceprevir—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00527	0.00904	CcSEcCtD
Boceprevir—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.0052	0.00892	CcSEcCtD
Boceprevir—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00517	0.00886	CcSEcCtD
Boceprevir—CTSK—spinal cord—amyotrophic lateral sclerosis	0.00514	0.0211	CbGeAlD
Boceprevir—Gout—Riluzole—amyotrophic lateral sclerosis	0.00513	0.0088	CcSEcCtD
Boceprevir—CTSS—medulla oblongata—amyotrophic lateral sclerosis	0.00505	0.0207	CbGeAlD
Boceprevir—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.00488	0.00837	CcSEcCtD
Boceprevir—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00485	0.00832	CcSEcCtD
Boceprevir—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00479	0.00822	CcSEcCtD
Boceprevir—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.00476	0.00817	CcSEcCtD
Boceprevir—CTSV—MHC class II antigen presentation—DCTN1—amyotrophic lateral sclerosis	0.00471	0.0273	CbGpPWpGaD
Boceprevir—CTSL—MHC class II antigen presentation—DCTN1—amyotrophic lateral sclerosis	0.00471	0.0273	CbGpPWpGaD
Boceprevir—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00457	0.00784	CcSEcCtD
Boceprevir—CTSS—spinal cord—amyotrophic lateral sclerosis	0.00451	0.0185	CbGeAlD
Boceprevir—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.0045	0.00771	CcSEcCtD
Boceprevir—CTSL—brain—amyotrophic lateral sclerosis	0.0044	0.018	CbGeAlD
Boceprevir—CTSK—nervous system—amyotrophic lateral sclerosis	0.00433	0.0177	CbGeAlD
Boceprevir—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00433	0.00743	CcSEcCtD
Boceprevir—CTSK—central nervous system—amyotrophic lateral sclerosis	0.00417	0.0171	CbGeAlD
Boceprevir—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00416	0.00713	CcSEcCtD
Boceprevir—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00416	0.00713	CcSEcCtD
Boceprevir—CTSK—RANKL/RANK Signaling Pathway—SQSTM1—amyotrophic lateral sclerosis	0.00409	0.0237	CbGpPWpGaD
Boceprevir—CTSK—cerebellum—amyotrophic lateral sclerosis	0.00408	0.0167	CbGeAlD
Boceprevir—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00408	0.00699	CcSEcCtD
Boceprevir—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.004	0.00686	CcSEcCtD
Boceprevir—CTSK—MHC class II antigen presentation—DCTN1—amyotrophic lateral sclerosis	0.0039	0.0226	CbGpPWpGaD
Boceprevir—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00389	0.00667	CcSEcCtD
Boceprevir—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00387	0.00664	CcSEcCtD
Boceprevir—CTSS—nervous system—amyotrophic lateral sclerosis	0.0038	0.0156	CbGeAlD
Boceprevir—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.0037	0.00635	CcSEcCtD
Boceprevir—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00369	0.00632	CcSEcCtD
Boceprevir—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00367	0.00629	CcSEcCtD
Boceprevir—CTSS—central nervous system—amyotrophic lateral sclerosis	0.00366	0.015	CbGeAlD
Boceprevir—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00358	0.00614	CcSEcCtD
Boceprevir—CTSS—cerebellum—amyotrophic lateral sclerosis	0.00357	0.0146	CbGeAlD
Boceprevir—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00342	0.00587	CcSEcCtD
Boceprevir—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00342	0.00587	CcSEcCtD
Boceprevir—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.0034	0.00582	CcSEcCtD
Boceprevir—CTSK—brain—amyotrophic lateral sclerosis	0.00331	0.0136	CbGeAlD
Boceprevir—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00329	0.00565	CcSEcCtD
Boceprevir—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00323	0.00555	CcSEcCtD
Boceprevir—CTSS—MHC class II antigen presentation—DCTN1—amyotrophic lateral sclerosis	0.00321	0.0186	CbGpPWpGaD
Boceprevir—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00317	0.00543	CcSEcCtD
Boceprevir—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00314	0.00539	CcSEcCtD
Boceprevir—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00308	0.00528	CcSEcCtD
Boceprevir—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00307	0.00526	CcSEcCtD
Boceprevir—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00303	0.00519	CcSEcCtD
Boceprevir—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00301	0.00515	CcSEcCtD
Boceprevir—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00301	0.00515	CcSEcCtD
Boceprevir—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00295	0.00505	CcSEcCtD
Boceprevir—CTSS—brain—amyotrophic lateral sclerosis	0.0029	0.0119	CbGeAlD
Boceprevir—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00289	0.00496	CcSEcCtD
Boceprevir—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00288	0.00494	CcSEcCtD
Boceprevir—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00285	0.0049	CcSEcCtD
Boceprevir—CMA1—Metabolism of proteins—IGFALS—amyotrophic lateral sclerosis	0.00283	0.0164	CbGpPWpGaD
Boceprevir—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00482	CcSEcCtD
Boceprevir—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00482	CcSEcCtD
Boceprevir—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00476	CcSEcCtD
Boceprevir—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00277	0.00475	CcSEcCtD
Boceprevir—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00274	0.00471	CcSEcCtD
Boceprevir—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00272	0.00466	CcSEcCtD
Boceprevir—CTSV—Activation of Matrix Metalloproteinases—MMP9—amyotrophic lateral sclerosis	0.0027	0.0157	CbGpPWpGaD
Boceprevir—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.0027	0.00462	CcSEcCtD
Boceprevir—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00268	0.0046	CcSEcCtD
Boceprevir—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00268	0.0046	CcSEcCtD
Boceprevir—Depression—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00458	CcSEcCtD
Boceprevir—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00451	CcSEcCtD
Boceprevir—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00261	0.00448	CcSEcCtD
Boceprevir—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00261	0.00447	CcSEcCtD
Boceprevir—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00435	CcSEcCtD
Boceprevir—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00434	CcSEcCtD
Boceprevir—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00251	0.00431	CcSEcCtD
Boceprevir—CMA1—Activation of Matrix Metalloproteinases—MMP9—amyotrophic lateral sclerosis	0.00251	0.0146	CbGpPWpGaD
Boceprevir—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.0025	0.00429	CcSEcCtD
Boceprevir—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00241	0.00414	CcSEcCtD
Boceprevir—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00239	0.00411	CcSEcCtD
Boceprevir—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00239	0.0041	CcSEcCtD
Boceprevir—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00238	0.00407	CcSEcCtD
Boceprevir—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00406	CcSEcCtD
Boceprevir—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00405	CcSEcCtD
Boceprevir—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00404	CcSEcCtD
Boceprevir—CTSL—Collagen degradation—MMP9—amyotrophic lateral sclerosis	0.00236	0.0136	CbGpPWpGaD
Boceprevir—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00228	0.0039	CcSEcCtD
Boceprevir—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00225	0.00386	CcSEcCtD
Boceprevir—CTSK—Activation of Matrix Metalloproteinases—MMP9—amyotrophic lateral sclerosis	0.00224	0.013	CbGpPWpGaD
Boceprevir—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00223	0.00383	CcSEcCtD
Boceprevir—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00374	CcSEcCtD
Boceprevir—CTSV—Toll-Like Receptors Cascades—ATF1—amyotrophic lateral sclerosis	0.00218	0.0126	CbGpPWpGaD
Boceprevir—CTSL—Toll-Like Receptors Cascades—ATF1—amyotrophic lateral sclerosis	0.00218	0.0126	CbGpPWpGaD
Boceprevir—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00217	0.00373	CcSEcCtD
Boceprevir—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00217	0.00372	CcSEcCtD
Boceprevir—Chills—Riluzole—amyotrophic lateral sclerosis	0.00216	0.0037	CcSEcCtD
Boceprevir—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00215	0.00369	CcSEcCtD
Boceprevir—CMA1—Metabolism of proteins—PIGW—amyotrophic lateral sclerosis	0.00214	0.0124	CbGpPWpGaD
Boceprevir—CTSV—Endochondral Ossification—IGF1—amyotrophic lateral sclerosis	0.00213	0.0124	CbGpPWpGaD
Boceprevir—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00365	CcSEcCtD
Boceprevir—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00361	CcSEcCtD
Boceprevir—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00359	CcSEcCtD
Boceprevir—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00354	CcSEcCtD
Boceprevir—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00352	CcSEcCtD
Boceprevir—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00203	0.00347	CcSEcCtD
Boceprevir—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00345	CcSEcCtD
Boceprevir—CMA1—Metabolism of proteins—XRN2—amyotrophic lateral sclerosis	0.00196	0.0113	CbGpPWpGaD
Boceprevir—CTSK—Collagen degradation—MMP9—amyotrophic lateral sclerosis	0.00195	0.0113	CbGpPWpGaD
Boceprevir—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00194	0.00333	CcSEcCtD
Boceprevir—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00194	0.00332	CcSEcCtD
Boceprevir—CMA1—Signaling by SCF-KIT—CASP9—amyotrophic lateral sclerosis	0.00193	0.0112	CbGpPWpGaD
Boceprevir—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00192	0.0033	CcSEcCtD
Boceprevir—CTSL—Adaptive Immune System—KIFAP3—amyotrophic lateral sclerosis	0.00192	0.0111	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—KIFAP3—amyotrophic lateral sclerosis	0.00192	0.0111	CbGpPWpGaD
Boceprevir—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00328	CcSEcCtD
Boceprevir—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00324	CcSEcCtD
Boceprevir—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00323	CcSEcCtD
Boceprevir—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00322	CcSEcCtD
Boceprevir—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00187	0.00322	CcSEcCtD
Boceprevir—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00317	CcSEcCtD
Boceprevir—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00316	CcSEcCtD
Boceprevir—CTSV—Assembly of collagen fibrils and other multimeric structures—MMP9—amyotrophic lateral sclerosis	0.00183	0.0106	CbGpPWpGaD
Boceprevir—CTSL—Assembly of collagen fibrils and other multimeric structures—MMP9—amyotrophic lateral sclerosis	0.00183	0.0106	CbGpPWpGaD
Boceprevir—Cough—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00313	CcSEcCtD
Boceprevir—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00181	0.0031	CcSEcCtD
Boceprevir—CTSK—Toll-Like Receptors Cascades—ATF1—amyotrophic lateral sclerosis	0.0018	0.0104	CbGpPWpGaD
Boceprevir—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00306	CcSEcCtD
Boceprevir—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00306	CcSEcCtD
Boceprevir—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00306	CcSEcCtD
Boceprevir—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00305	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00304	CcSEcCtD
Boceprevir—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00302	CcSEcCtD
Boceprevir—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00299	CcSEcCtD
Boceprevir—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00296	CcSEcCtD
Boceprevir—Infection—Riluzole—amyotrophic lateral sclerosis	0.0017	0.00291	CcSEcCtD
Boceprevir—Shock—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00288	CcSEcCtD
Boceprevir—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00287	CcSEcCtD
Boceprevir—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00287	CcSEcCtD
Boceprevir—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00286	CcSEcCtD
Boceprevir—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00285	CcSEcCtD
Boceprevir—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00283	CcSEcCtD
Boceprevir—CMA1—Signaling by SCF-KIT—ERBB4—amyotrophic lateral sclerosis	0.00165	0.00956	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—YIF1A—amyotrophic lateral sclerosis	0.00162	0.0094	CbGpPWpGaD
Boceprevir—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00274	CcSEcCtD
Boceprevir—CTSK—Adaptive Immune System—KIFAP3—amyotrophic lateral sclerosis	0.00159	0.00921	CbGpPWpGaD
Boceprevir—CMA1—Peptide hormone metabolism—IGF1—amyotrophic lateral sclerosis	0.00158	0.00916	CbGpPWpGaD
Boceprevir—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00267	CcSEcCtD
Boceprevir—CTSV—Endochondral Ossification—MMP9—amyotrophic lateral sclerosis	0.00155	0.00899	CbGpPWpGaD
Boceprevir—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00265	CcSEcCtD
Boceprevir—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00263	CcSEcCtD
Boceprevir—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00261	CcSEcCtD
Boceprevir—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00258	CcSEcCtD
Boceprevir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.0015	0.00869	CbGpPWpGaD
Boceprevir—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00255	CcSEcCtD
Boceprevir—CTSS—Toll-Like Receptors Cascades—ATF1—amyotrophic lateral sclerosis	0.00149	0.00861	CbGpPWpGaD
Boceprevir—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00253	CcSEcCtD
Boceprevir—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00253	CcSEcCtD
Boceprevir—Pain—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00251	CcSEcCtD
Boceprevir—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00251	CcSEcCtD
Boceprevir—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00242	CcSEcCtD
Boceprevir—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.0014	0.0024	CcSEcCtD
Boceprevir—ABCB1—embryo—amyotrophic lateral sclerosis	0.0014	0.00571	CbGeAlD
Boceprevir—CTSV—Endochondral Ossification—VEGFA—amyotrophic lateral sclerosis	0.00139	0.00807	CbGpPWpGaD
Boceprevir—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00233	CcSEcCtD
Boceprevir—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00232	CcSEcCtD
Boceprevir—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00232	CcSEcCtD
Boceprevir—CMA1—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	0.00134	0.00774	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—KIFAP3—amyotrophic lateral sclerosis	0.00131	0.00758	CbGpPWpGaD
Boceprevir—CTSV—Degradation of the extracellular matrix—CASP3—amyotrophic lateral sclerosis	0.00126	0.00731	CbGpPWpGaD
Boceprevir—CTSL—Degradation of the extracellular matrix—CASP3—amyotrophic lateral sclerosis	0.00126	0.00731	CbGpPWpGaD
Boceprevir—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00216	CcSEcCtD
Boceprevir—CTSS—Assembly of collagen fibrils and other multimeric structures—MMP9—amyotrophic lateral sclerosis	0.00125	0.00724	CbGpPWpGaD
Boceprevir—CTSL—Collagen formation—MMP9—amyotrophic lateral sclerosis	0.00125	0.00723	CbGpPWpGaD
Boceprevir—CTSV—Collagen formation—MMP9—amyotrophic lateral sclerosis	0.00125	0.00723	CbGpPWpGaD
Boceprevir—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00123	0.0021	CcSEcCtD
Boceprevir—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00207	CcSEcCtD
Boceprevir—CTSL—Degradation of the extracellular matrix—MMP9—amyotrophic lateral sclerosis	0.00119	0.00691	CbGpPWpGaD
Boceprevir—CTSV—Degradation of the extracellular matrix—MMP9—amyotrophic lateral sclerosis	0.00119	0.00691	CbGpPWpGaD
Boceprevir—CMA1—Degradation of the extracellular matrix—CASP3—amyotrophic lateral sclerosis	0.00117	0.0068	CbGpPWpGaD
Boceprevir—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00201	CcSEcCtD
Boceprevir—CTSV—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.00116	0.00674	CbGpPWpGaD
Boceprevir—CTSL—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.00116	0.00674	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—DCTN1—amyotrophic lateral sclerosis	0.00113	0.00655	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—DCTN1—amyotrophic lateral sclerosis	0.00113	0.00655	CbGpPWpGaD
Boceprevir—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00194	CcSEcCtD
Boceprevir—CMA1—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	0.00112	0.00651	CbGpPWpGaD
Boceprevir—CMA1—Degradation of the extracellular matrix—MMP9—amyotrophic lateral sclerosis	0.00111	0.00642	CbGpPWpGaD
Boceprevir—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00186	CcSEcCtD
Boceprevir—Rash—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00185	CcSEcCtD
Boceprevir—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00185	CcSEcCtD
Boceprevir—Headache—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00184	CcSEcCtD
Boceprevir—CTSK—Degradation of the extracellular matrix—CASP3—amyotrophic lateral sclerosis	0.00105	0.00606	CbGpPWpGaD
Boceprevir—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00174	CcSEcCtD
Boceprevir—CTSK—Degradation of the extracellular matrix—MMP9—amyotrophic lateral sclerosis	0.000988	0.00572	CbGpPWpGaD
Boceprevir—CTSK—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000964	0.00558	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	0.000957	0.00554	CbGpPWpGaD
Boceprevir—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000946	0.00388	CbGeAlD
Boceprevir—CTSK—Adaptive Immune System—DCTN1—amyotrophic lateral sclerosis	0.000937	0.00543	CbGpPWpGaD
Boceprevir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000924	0.00535	CbGpPWpGaD
Boceprevir—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000911	0.00373	CbGeAlD
Boceprevir—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000891	0.00365	CbGeAlD
Boceprevir—CTSS—Degradation of the extracellular matrix—CASP3—amyotrophic lateral sclerosis	0.000861	0.00499	CbGpPWpGaD
Boceprevir—CTSS—Collagen formation—MMP9—amyotrophic lateral sclerosis	0.000852	0.00494	CbGpPWpGaD
Boceprevir—CTSS—Degradation of the extracellular matrix—MMP9—amyotrophic lateral sclerosis	0.000814	0.00471	CbGpPWpGaD
Boceprevir—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000795	0.00326	CbGeAlD
Boceprevir—CTSS—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000794	0.0046	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—DCTN1—amyotrophic lateral sclerosis	0.000772	0.00447	CbGpPWpGaD
Boceprevir—CMA1—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	0.000767	0.00444	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	0.000706	0.00409	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.000705	0.00409	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.000705	0.00409	CbGpPWpGaD
Boceprevir—CTSL—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000686	0.00397	CbGpPWpGaD
Boceprevir—CTSV—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000686	0.00397	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.000672	0.00389	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.000672	0.00389	CbGpPWpGaD
Boceprevir—ABCB1—nervous system—amyotrophic lateral sclerosis	0.00067	0.00274	CbGeAlD
Boceprevir—CTSL—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.000645	0.00374	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.000645	0.00374	CbGpPWpGaD
Boceprevir—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000645	0.00264	CbGeAlD
Boceprevir—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.00063	0.00258	CbGeAlD
Boceprevir—CTSK—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.000585	0.00338	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000575	0.00333	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000575	0.00333	CbGpPWpGaD
Boceprevir—CTSK—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000568	0.00329	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.000557	0.00322	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	0.000552	0.0032	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	0.000552	0.0032	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.000535	0.0031	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—CASP3—amyotrophic lateral sclerosis	0.000529	0.00306	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—CASP3—amyotrophic lateral sclerosis	0.000529	0.00306	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	0.000519	0.00301	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	0.000519	0.00301	CbGpPWpGaD
Boceprevir—CYP3A5—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000516	0.00299	CbGpPWpGaD
Boceprevir—ABCB1—brain—amyotrophic lateral sclerosis	0.000512	0.0021	CbGeAlD
Boceprevir—CMA1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000506	0.00293	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—MMP9—amyotrophic lateral sclerosis	0.0005	0.00289	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—MMP9—amyotrophic lateral sclerosis	0.0005	0.00289	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—CASP3—amyotrophic lateral sclerosis	0.000492	0.00285	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.000481	0.00279	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—C3—amyotrophic lateral sclerosis	0.000478	0.00277	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—C3—amyotrophic lateral sclerosis	0.000478	0.00277	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000476	0.00276	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000475	0.00275	CbGpPWpGaD
Boceprevir—CTSS—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000468	0.00271	CbGpPWpGaD
Boceprevir—CMA1—Extracellular matrix organization—MMP9—amyotrophic lateral sclerosis	0.000465	0.00269	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000463	0.00268	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—C3—amyotrophic lateral sclerosis	0.000459	0.00266	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—C3—amyotrophic lateral sclerosis	0.000459	0.00266	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.000458	0.00265	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	0.000458	0.00265	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000451	0.00261	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.00044	0.00255	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—CASP3—amyotrophic lateral sclerosis	0.000438	0.00254	CbGpPWpGaD
Boceprevir—CTSL—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000438	0.00254	CbGpPWpGaD
Boceprevir—CTSV—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000438	0.00254	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000437	0.00253	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	0.00043	0.00249	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—MMP9—amyotrophic lateral sclerosis	0.000414	0.0024	CbGpPWpGaD
Boceprevir—CTSL—Immune System—ATF1—amyotrophic lateral sclerosis	0.000411	0.00238	CbGpPWpGaD
Boceprevir—CTSV—Immune System—ATF1—amyotrophic lateral sclerosis	0.000411	0.00238	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—C3—amyotrophic lateral sclerosis	0.000396	0.00229	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000392	0.00227	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CASP9—amyotrophic lateral sclerosis	0.000391	0.00227	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CASP9—amyotrophic lateral sclerosis	0.000391	0.00227	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000388	0.00224	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000383	0.00222	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—C3—amyotrophic lateral sclerosis	0.00038	0.0022	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000377	0.00218	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	0.000377	0.00218	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.000371	0.00215	CbGpPWpGaD
Boceprevir—CTSK—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000363	0.0021	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—CASP3—amyotrophic lateral sclerosis	0.000361	0.00209	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	0.000354	0.00205	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—MMP9—amyotrophic lateral sclerosis	0.000341	0.00197	CbGpPWpGaD
Boceprevir—CTSK—Immune System—ATF1—amyotrophic lateral sclerosis	0.00034	0.00197	CbGpPWpGaD
Boceprevir—CTSL—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000335	0.00194	CbGpPWpGaD
Boceprevir—CTSV—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000335	0.00194	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—C3—amyotrophic lateral sclerosis	0.000326	0.00189	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CASP9—amyotrophic lateral sclerosis	0.000324	0.00188	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CD40LG—amyotrophic lateral sclerosis	0.000315	0.00182	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CD40LG—amyotrophic lateral sclerosis	0.000315	0.00182	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—C3—amyotrophic lateral sclerosis	0.000313	0.00181	CbGpPWpGaD
Boceprevir—CTSS—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000299	0.00173	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	0.000299	0.00173	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.000298	0.00173	CbGpPWpGaD
Boceprevir—CTSS—Immune System—ATF1—amyotrophic lateral sclerosis	0.00028	0.00162	CbGpPWpGaD
Boceprevir—CTSV—Immune System—C3—amyotrophic lateral sclerosis	0.000278	0.00161	CbGpPWpGaD
Boceprevir—CTSL—Immune System—C3—amyotrophic lateral sclerosis	0.000278	0.00161	CbGpPWpGaD
Boceprevir—CTSK—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000278	0.00161	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CASP9—amyotrophic lateral sclerosis	0.000267	0.00155	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000264	0.00153	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000263	0.00152	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CD40LG—amyotrophic lateral sclerosis	0.000261	0.00151	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000259	0.0015	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000252	0.00146	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000247	0.00143	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00024	0.00139	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000237	0.00137	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000235	0.00136	CbGpPWpGaD
Boceprevir—CYP3A5—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000231	0.00134	CbGpPWpGaD
Boceprevir—CTSK—Immune System—C3—amyotrophic lateral sclerosis	0.000231	0.00134	CbGpPWpGaD
Boceprevir—CTSS—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000229	0.00132	CbGpPWpGaD
Boceprevir—CYP3A5—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000228	0.00132	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000216	0.00125	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CD40LG—amyotrophic lateral sclerosis	0.000215	0.00124	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000201	0.00117	CbGpPWpGaD
Boceprevir—CTSS—Immune System—C3—amyotrophic lateral sclerosis	0.00019	0.0011	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000189	0.0011	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000183	0.00106	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000177	0.00102	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000177	0.00102	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000167	0.000969	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000162	0.000937	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.000156	0.000904	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000156	0.000902	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000154	0.000893	CbGpPWpGaD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	0.000153	0.000886	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00015	0.000871	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000147	0.000853	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000141	0.000819	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000139	0.000806	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000134	0.000773	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000134	0.000773	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	0.000133	0.000767	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000129	0.000745	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	0.000128	0.000741	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000122	0.000707	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000118	0.000686	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000118	0.000686	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000114	0.000657	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000107	0.000622	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000107	0.000618	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000106	0.000613	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000106	0.000611	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.0001	0.00058	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.91e-05	0.000574	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	9.7e-05	0.000561	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	9.65e-05	0.000559	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.36e-05	0.000542	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	8.95e-05	0.000518	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.41e-05	0.000487	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	8.3e-05	0.000481	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	8.23e-05	0.000476	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	8.23e-05	0.000476	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	7.71e-05	0.000446	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	7.52e-05	0.000436	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	7.35e-05	0.000426	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	7.32e-05	0.000424	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	7e-05	0.000405	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	6.75e-05	0.000391	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	6.58e-05	0.000381	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	6.54e-05	0.000379	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.35e-05	0.000368	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	5.95e-05	0.000344	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	5.54e-05	0.000321	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	4.94e-05	0.000286	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	4.51e-05	0.000261	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	4.16e-05	0.000241	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.95e-05	0.000229	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.63e-05	0.00021	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	3.42e-05	0.000198	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	2.99e-05	0.000173	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.98e-05	0.000173	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.74e-05	0.000159	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	2.25e-05	0.00013	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.05e-05	0.000118	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.84e-05	0.000106	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.69e-05	9.77e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.54e-05	8.94e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.39e-05	8.04e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.51e-06	5.51e-05	CbGpPWpGaD
